OKYO · OKYO Pharma Limited

Summary

OKYO Pharma Limited announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, generating gross proceeds of approximately $20 million, with an option for the underwriter to purchase up to an additional 1,622,250 shares. The company intends to use the net proceeds primarily for clinical development of its product candidates, general corporate purposes, and working capital.

Key takeaways

• OKYO Pharma priced a public offering of 10,815,000 ordinary shares at $1.85 per share.
• Gross proceeds to the company from the offering are approximately $20 million before expenses.
• The underwriter has a 30-day option to purchase up to an additional 1,622,250 shares.
• If the underwriter's option is fully exercised, gross proceeds would be approximately $23 million.
• Net proceeds will be used primarily for clinical development, general corporate purposes, and working capital.
• The offering is expected to close on or about February 17, 2026.